328 related articles for article (PubMed ID: 9744794)
1. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes.
Mailliot C; Sergeant N; Bussière T; Caillet-Boudin ML; Delacourte A; Buée L
FEBS Lett; 1998 Aug; 433(3):201-4. PubMed ID: 9744794
[TBL] [Abstract][Full Text] [Related]
2. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms.
Sergeant N; Wattez A; Delacourte A
J Neurochem; 1999 Mar; 72(3):1243-9. PubMed ID: 10037497
[TBL] [Abstract][Full Text] [Related]
3. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases.
Sergeant N; David JP; Lefranc D; Vermersch P; Wattez A; Delacourte A
FEBS Lett; 1997 Aug; 412(3):578-82. PubMed ID: 9276470
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
5. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease.
Buée L; Delacourte A
Brain Pathol; 1999 Oct; 9(4):681-93. PubMed ID: 10517507
[TBL] [Abstract][Full Text] [Related]
6. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2.
Adamec E; Mohan P; Vonsattel JP; Nixon RA
Acta Neuropathol; 2002 Jul; 104(1):92-104. PubMed ID: 12070670
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
8. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.
Martínez-Maldonado A; Ontiveros-Torres MÁ; Harrington CR; Montiel-Sosa JF; Prandiz RG; Bocanegra-López P; Sorsby-Vargas AM; Bravo-Muñoz M; Florán-Garduño B; Villanueva-Fierro I; Perry G; Garcés-Ramírez L; de la Cruz F; Martínez-Robles S; Pacheco-Herrero M; Luna-Muñoz J
J Alzheimers Dis; 2021; 79(4):1517-1531. PubMed ID: 33459640
[TBL] [Abstract][Full Text] [Related]
9. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease.
Buée Scherrer V; Hof PR; Buée L; Leveugle B; Vermersch P; Perl DP; Olanow CW; Delacourte A
Acta Neuropathol; 1996; 91(4):351-9. PubMed ID: 8928611
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias.
Delacourte A
Dement Geriatr Cogn Disord; 1999; 10 Suppl 1():75-9. PubMed ID: 10436346
[TBL] [Abstract][Full Text] [Related]
12. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
13. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting.
Scaravilli T; Tolosa E; Ferrer I
Mov Disord; 2005 Aug; 20 Suppl 12():S21-8. PubMed ID: 16092076
[TBL] [Abstract][Full Text] [Related]
14. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease.
Ishizawa K; Ksiezak-Reding H; Davies P; Delacourte A; Tiseo P; Yen SH; Dickson DW
Acta Neuropathol; 2000 Sep; 100(3):235-44. PubMed ID: 10965792
[TBL] [Abstract][Full Text] [Related]
15. Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities.
Mailliot C; Bussière T; Hamdane M; Sergeant N; Caillet ML; Delacourte A; Buée L
Ann N Y Acad Sci; 2000; 920():107-14. PubMed ID: 11193138
[TBL] [Abstract][Full Text] [Related]
16. Tau protein pathology in neurodegenerative diseases.
Spillantini MG; Goedert M
Trends Neurosci; 1998 Oct; 21(10):428-33. PubMed ID: 9786340
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
18. Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles.
Takahashi M; Uchikado H; Caprotti D; Weidenheim KM; Dickson DW; Ksiezak-Reding H; Pasinetti GM
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1157-69. PubMed ID: 17146290
[TBL] [Abstract][Full Text] [Related]
19. REVIEW: tau protein pathology in Alzheimer's disease and related disorders.
Tolnay M; Probst A
Neuropathol Appl Neurobiol; 1999 Jun; 25(3):171-87. PubMed ID: 10417659
[TBL] [Abstract][Full Text] [Related]
20. Tangle evolution linked to differential 3- and 4-repeat tau isoform deposition: a double immunofluorolabeling study using two monoclonal antibodies.
Uchihara T; Hara M; Nakamura A; Hirokawa K
Histochem Cell Biol; 2012 Feb; 137(2):261-7. PubMed ID: 22116524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
